BioCentury | May 15, 2020
Product Development

Novartis R&D heads Bradner and Tsai see hard lessons and hope in coronavirus research

If industry had responded to the first SARS outbreak the way it is now, we would probably have drugs on hand to treat COVID-19. That sobering conclusion was evident, said NIBR’s Jay Bradner, when the...
BioCentury | Apr 24, 2020
Product Development

April 23 Quick Takes: Hansoh, NiKang partner for antiviral; plus Jakafi, Avastin, EpimAb-QIMR, ProThera-Takeda

Hansoh gains China rights to NiKang antiviral  Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692) gained rights to develop and commercialize NKT-1992 from NiKang Therapeutics Inc. for viral diseases in Greater China. NiKang is eligible to receive...
BioCentury | Apr 9, 2020
Product Development

Pfizer’s COVID-19 push: antiviral candidate identified as anti-inflammatory Xeljanz starts trial

For its latest COVID-19 initiatives, Pfizer has identified a lead antiviral candidate and announced the planned start of a Phase II study of anti-inflammatory Xeljanz in Italy. The updates came as the pharma unveiled details...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership...
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...
BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BC Extra | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the...
BC Extra | Jan 3, 2020
Clinical News

As itacitinib stumbles in acute GvHD, Incyte turns to chronic setting

Incyte’s discontinuation of itacitinib’s development in acute graft-versus-host disease after a Phase III miss has muddied the outlook for the JAK-1 inhibitor in the larger setting of chronic GvHD and marks a setback as the...
BC Extra | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

December’s rush of follow-ons has continued with Rocket, Constellation and Marinus all pricing follow-on offerings since Tuesday’s close to raise more than $340 million. But cash raised via follow-ons continues to lag behind last year's...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
Items per page:
1 - 10 of 279